Financings In Brief: Neurogen
Executive Summary
Neurogen: Nets $37.7 mil. (before expenses) from its offering of 2.5 mil. shares of common stock at $16 per share, the Branford, Conn.-based company announces. Psychopharmacological and CNS drug R&D firm plans to use the proceeds to fund R&D, including clinical development of an atypical antipsychotic agent and a diagnostic aid for schizophrenia, both in early stages...